2-(3-fluorophenethoxy)acetaldehyde | 1018909-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-fluorophenethoxy)acetaldehyde
• 英文别名: 2-[2-(3-Fluorophenyl)ethoxy]acetaldehyde
• CAS: 1018909-69-7
• 化学式: C₁₀H₁₁FO₂
• 分子量: 182.195
• InChiKey: PTTKGCWTYYPYPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-fluorophenethoxy)acetaldehyde 、 tert-butyl 3-amino-4-((6-(tert-butoxycarbonylamino)-4-methylpyridin-2-yl)methyl)pyrrolidine-1-carboxylate 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.25h， 以78%的产率得到(+/-)-cis-tert-butyl 3-{[6-(tert-butoxycarbonylamino)-4-methylpyridin-2-yl]methyl}-4-[2-(3-fluorophenethoxy)ethylamino]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  WO2008/42353

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(2-(烯丙氧基)乙基)-3-氟苯 在 臭氧 、 溶剂黄146 、 锌 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 以80%的产率得到2-(3-fluorophenethoxy)acetaldehyde
  参考文献：
  名称：

  Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability

  摘要：

  Overproduction of nitric oxide by neuronal nitric oxide synthase ( nNOS) has been linked to several neurodegenerative diseases. We have recently designed potent and isoform selective inhibitors of nNOS, but the lead compound contains several basic functional groups. A large number of charges and hydrogen bond donors can impede the ability of molecules to cross the blood brain barrier and thereby limit the effectiveness of potential neurological therapeutics. Replacement of secondary amines in our lead compound with neutral ether and amide groups was made to increase bioavailability and to determine if the potency and selectivity of the inhibitor would be impacted. An ether analogue has been identified that retains a similar potency and selectivity to that of the lead compound, and shows increased ability to penetrate the blood brain barrier. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.02.017

文献信息

• Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase
  申请人：Silverman B. Richard

  公开号：US20080108814A1

  公开（公告）日：2008-05-08

  Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.

  肽类类似物化合物可抑制神经元一氧化氮合酶(nNOS)，用于潜在的治疗神经退行性疾病，如中风、阿尔茨海默病、帕金森病、亨廷顿病等。
• US7994326B2
  申请人：——

  公开号：US7994326B2

  公开（公告）日：2011-08-09
• [EN] POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE<br/>[FR] INHIBITEURS HÉTÉROAROMATIQUES PUISSANTS ET HAUTEMENT SÉLECTIFS DE LA MONOXYDE D'AZOTE SYNTHASE NEURONALE
  申请人：UNIV NORTHWESTERN

  公开号：WO2008042353A1

  公开（公告）日：2008-04-10

  [EN] Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.
  [FR] L'invention concerne des composés peptidomimétiques capables d'inhiber la monoxyde d'azote synthase neuronale (nNOS) dans le traitement potentiel de maladies neurodégénératives, telles que, mais sans en exclure d'autres, l'accident vasculaire cérébral, la maladie d'Alzheimer, la maladie de Parkinson et la maladie de Huntington.
• WO2008/42353
  申请人：——

  公开号：——

  公开（公告）日：——
• Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability
  作者：Graham R. Lawton、Hantamalala Ralay Ranaivo、Laura K. Chico、Haitao Ji、Fengtian Xue、Pavel Martásek、Linda J. Roman、D. Martin Watterson、Richard B. Silverman

  DOI：10.1016/j.bmc.2009.02.017

  日期：2009.3

  Overproduction of nitric oxide by neuronal nitric oxide synthase ( nNOS) has been linked to several neurodegenerative diseases. We have recently designed potent and isoform selective inhibitors of nNOS, but the lead compound contains several basic functional groups. A large number of charges and hydrogen bond donors can impede the ability of molecules to cross the blood brain barrier and thereby limit the effectiveness of potential neurological therapeutics. Replacement of secondary amines in our lead compound with neutral ether and amide groups was made to increase bioavailability and to determine if the potency and selectivity of the inhibitor would be impacted. An ether analogue has been identified that retains a similar potency and selectivity to that of the lead compound, and shows increased ability to penetrate the blood brain barrier. (C) 2009 Elsevier Ltd. All rights reserved.